Teacher Retirement System of Texas Purchases 2,410 Shares of Arcus Biosciences, Inc. (NYSE:RCUS)

Teacher Retirement System of Texas lifted its position in shares of Arcus Biosciences, Inc. (NYSE:RCUS) by 19.2% during the 4th quarter, HoldingsChannel reports. The firm owned 14,952 shares of the company’s stock after acquiring an additional 2,410 shares during the period. Teacher Retirement System of Texas’ holdings in Arcus Biosciences were worth $223,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. R Squared Ltd bought a new stake in shares of Arcus Biosciences in the 4th quarter worth approximately $26,000. Point72 Hong Kong Ltd purchased a new position in Arcus Biosciences during the third quarter valued at $47,000. US Bancorp DE boosted its holdings in Arcus Biosciences by 2,432.0% in the fourth quarter. US Bancorp DE now owns 6,887 shares of the company’s stock worth $103,000 after acquiring an additional 6,615 shares in the last quarter. Intech Investment Management LLC bought a new position in shares of Arcus Biosciences during the third quarter valued at $244,000. Finally, Martingale Asset Management L P purchased a new position in shares of Arcus Biosciences in the 3rd quarter worth about $251,000. 92.89% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Arcus Biosciences

In other Arcus Biosciences news, CEO Terry J. Rosen bought 19,800 shares of Arcus Biosciences stock in a transaction dated Thursday, February 27th. The shares were purchased at an average cost of $10.18 per share, for a total transaction of $201,564.00. Following the acquisition, the chief executive officer now directly owns 2,554,160 shares in the company, valued at approximately $26,001,348.80. This represents a 0.78 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, Director Yasunori Kaneko acquired 20,000 shares of the stock in a transaction dated Thursday, February 27th. The stock was bought at an average cost of $10.06 per share, with a total value of $201,200.00. Following the completion of the purchase, the director now directly owns 28,400 shares in the company, valued at approximately $285,704. The trade was a 238.10 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 12.30% of the company’s stock.

Analysts Set New Price Targets

RCUS has been the topic of several analyst reports. Bank of America dropped their target price on shares of Arcus Biosciences from $22.00 to $17.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 19th. Morgan Stanley lowered their price objective on Arcus Biosciences from $36.00 to $25.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 18th. Finally, HC Wainwright upgraded Arcus Biosciences from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $18.00 to $24.00 in a research note on Wednesday, February 26th. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Arcus Biosciences presently has a consensus rating of “Buy” and a consensus price target of $30.25.

Arcus Biosciences Price Performance

NYSE:RCUS opened at $7.70 on Wednesday. The business’s 50-day simple moving average is $10.86 and its two-hundred day simple moving average is $14.18. Arcus Biosciences, Inc. has a 52 week low of $7.51 and a 52 week high of $18.98. The stock has a market cap of $809.04 million, a PE ratio of -2.44 and a beta of 1.36. The company has a quick ratio of 5.24, a current ratio of 5.24 and a debt-to-equity ratio of 0.08.

Arcus Biosciences (NYSE:RCUS) last issued its earnings results on Tuesday, February 25th. The company reported ($1.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.17) by $0.14. Arcus Biosciences had a negative return on equity of 45.59% and a negative net margin of 102.66%. The company had revenue of $36.00 million for the quarter, compared to the consensus estimate of $29.38 million. As a group, analysts forecast that Arcus Biosciences, Inc. will post -3.15 EPS for the current fiscal year.

Arcus Biosciences Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.